Analysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $42.20

Omnicell, Inc. (NASDAQ:OMCLGet Free Report) has been assigned a consensus rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $42.20.

A number of research analysts have weighed in on OMCL shares. Barclays started coverage on shares of Omnicell in a research note on Wednesday, January 3rd. They issued an “underweight” rating and a $33.00 price target on the stock. Wells Fargo & Company cut their price target on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. Finally, Benchmark cut their price target on shares of Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, February 9th.

Read Our Latest Research Report on OMCL

Omnicell Stock Down 0.0 %

Omnicell stock opened at $29.23 on Friday. The company’s 50 day simple moving average is $29.23 and its 200 day simple moving average is $35.14. Omnicell has a fifty-two week low of $25.69 and a fifty-two week high of $77.14. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -64.96 and a beta of 0.74. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22.

Omnicell (NASDAQ:OMCLGet Free Report) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. Omnicell had a negative net margin of 1.78% and a positive return on equity of 3.43%. The business had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. As a group, sell-side analysts anticipate that Omnicell will post 0.1 EPS for the current year.

Institutional Trading of Omnicell

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Omnicell by 8.5% in the fourth quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company’s stock valued at $209,653,000 after purchasing an additional 434,336 shares during the last quarter. Macquarie Group Ltd. increased its holdings in Omnicell by 12.5% during the second quarter. Macquarie Group Ltd. now owns 1,218,279 shares of the company’s stock worth $138,579,000 after buying an additional 135,360 shares during the last quarter. Clearbridge Investments LLC increased its holdings in Omnicell by 8.9% during the first quarter. Clearbridge Investments LLC now owns 1,136,664 shares of the company’s stock worth $147,187,000 after buying an additional 92,567 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Omnicell by 2.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,067,516 shares of the company’s stock worth $40,173,000 after buying an additional 21,798 shares during the last quarter. Finally, Pacer Advisors Inc. increased its holdings in Omnicell by 321,488.8% during the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock worth $39,814,000 after buying an additional 1,057,698 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

(Get Free Report

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Articles

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.